Interactions of pharmacologically active snake venom sPLA₂ with different cell lines

Figures & data

Figure 1. (A) Kinetics of MDCK II cells treatment with sPLA₂ (1.5 × 10⁻⁶ mol L⁻¹ and Trypan blue staining at 30 min). (B) In vitro cytotoxic effect of pure sPLA₂ (0.5 to 1.5 × 10⁻⁶ mol L⁻¹ on MDCK II cells after two hours of exposure to different snake venom sPLA₂ concentrations. Cell viability is determined by MTT assay (the MTT value of control sample exposed only to PBS buffer is defined as 100% viability). Data from the experiments performed in triplicate are expressed as mean ± SD.

Figure 2. (A) Kinetics of Best-transfected MDCK II cells treatment with PLA₂ (1.5 × 10⁻⁶ mol L⁻¹ and Trypan blue staining at 30 min). (B) In vitro cytotoxic effect of pure sPLA₂ (0.5 to 1.5 × 10⁻⁶ mol L⁻¹ on MDCK II-Best1 cells after two hours exposure to different snake venom sPLA₂ concentrations.

Figure 3. (A) Kinetics of A549 cells treatment with PLA₂ (1.5 × 10⁻⁶ mol L^{− 1} and Trypan blue staining at 30 min). (B) In vitro cytotoxic effect of pure sPLA₂ (0.5 to 1.5 × 10⁻⁶ mol L⁻¹ on A549 cells after two hours of exposure to different snake venom sPLA₂ concentrations.

Figure 4. (A) Kinetics of RPE-1 cells treatment with PLA₂ (1.5 × 10⁻⁶ mol L⁻¹ and Trypan blue staining at 30 min). (B) In vitro cytotoxic effect of pure sPLA₂ (0.5 to 1.5 × 10⁻⁶ mol L⁻¹ on RPE-1 cells after two hours of exposure to different snake venom sPLA₂ concentrations.

Figure 5. Fluorescence micrographs of MDCK II (A) and RPE-1 (B) cells after incubation with 1.5 × 10⁻⁶ mol L⁻¹ ANS-labelled sPLA₂.